Drug Trial Radar · NCT03896737
Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara
Last checked: Nov 20, 2026Latest source record: Jul 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
401
Actual
Start
Apr 16, 2019
Primary completion
Jun 30, 2026
Study completion Sep 15, 2027
Sponsor
- Lead sponsor
- European Myeloma Network B.V.Research network
- Sponsor type
- Research network
- Collaborators
- EMN Trial Office S.r.l. Impresa Sociale
- First posted
- Apr 1, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol is a phase II multicenter, randomized, open label study designed to assess the efficacy and safety of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus the association of bortezomib, thalidomide and dexamethasone (VTd) as pre transplant induction and post transplant consolidation, followed by maintenance with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) patients eligible for autologous stem cell transplantation. Patients enrolled in the Dara-VCd arm will receive: 4 cycles of daratumumab-bortezomib-cyclophosphamide-dexamethasone induction, followed by transplantation and 2 cycles of daratumumab-bortezomib-cyclophosphamide-dexamethasone consolidation. The choice of cyclophosphamide in combination with bortezomib and dexamethasone is suggested by the better safety profile of cyclophosphamide, in comparison with thalidomide and the efficacy of the alkylator agent, when combined with bortezomib. Once-weekly bortezomib seems to be equally effective and better tolerated than the standard twice weekly schedule. The outcomes and response rate did not appear to be affected by the bortezomib dosing schedule. Patients enrolled in the VTd arm will receive: 4 cycles of bortezomib-thalidomide-dexamethasone induction, followed by autologous transplantation and 2 cycles of bortezomib-thalidomide dexamethasone as consolidation. The VTd drug association is the current standard first line induction therapy for multiple myeloma patients who are eligible to stem cell transplantation. At the end of consolidation phase patients with at least a partial response (≥ PR) will be rerandomized (assigned by chance) to one of 2 treatment groups to receive maintenance treatment with ixazomib alone or in combination with daratumumab. Patients will receive treatment until any sign of progression or intolerance, up to 24 months.
Conditions
- Multiple Myeloma
Interventions
Daratumumab plus Velcade Cyclophosphamide DexamethasoneDrug
To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Velcade Thalidomide DexamethasoneDrug
To compare Dara-VCd versus VTd as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with Ixazomib alone or in combination with Daratumumab, in newly diagnosed Multiple Myeloma (MM) young patients eligible for autologous stem cell transplantation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survival (PFS)Time frame: 5 years
- MRD negativityTime frame: 5 years
Locations
24 sites in 3 countries. Site status is shown where the registry gives one.
Hradec Kralove-University Hospital Hradec Kralove
Hradec Králové, Czechia
University Hospital Olomouc
Olomouc, Czechia
University Hospital Ostrava
Ostrava, Czechia
University Hospital Ostrava
Ostrava, Czechia
University Hospital Plzen
Pilsen, Czechia
General University Hospital (VFN)-Internal Medicine, Hematology Clinic
Prague, Czechia
General Hospital of Athens "Alexandra"
Athens, Greece
General Hospital of Athens 'Evangelismos
Athens, Greece
University General Hospital of Patras
Pátrai, Greece
A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di Ancona
Ancona, Italy
A.O. Papa Giovanni XXIII
Bergamo, Italy
Policlinico S. Orsola
Bologna, Italy
A.O. Spedali Civili di brescia
Brescia, Italy
A.O.U. Policlinico Vittorio Emanuele di Catania
Catania, Italy
A.O.U. Policlinico San Martino
Genova, Italy
Ospedale Niguarda
Milan, Italy
A.O.U. Maggiore della Carità di Novara
Novara, Italy
Dipartimento Medicina Clinica e Sperimentale - AO di Padova
Padova, Italy
Policlinico S. Matteo Fondazione IRCCS
Pavia, Italy
A.O. di Perugia-Ospedale S. Maria della Misericordia
Perugia, Italy
Arcispedale S. Maria Nuova
Reggio Emilia, Italy
I.R.C.C.S. Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Italy
Az. Osp. S. Maria
Terni, Italy
AOU Città della Salute e della Scienza di Torino
Torino, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.